EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sertraline Administration to Prevent Intradialytic Hypotension: A Randomized, Double-Blind, Placebo-Controlled Crossover Study (SLATAN Study)

Prit Kusirisin, Chidchanok Ruengorn iD, Surapon Nochaiwong iD, Kajohnsak Noppakun iD

American Journal of Nephrology · 10.11.2026

DOI: 10.1159/ajn/ablag035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Nephrology, online erschienen am 10.11.2026. Verfasst von Prit Kusirisin und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Intradialytic hypotension (IDH) is common during hemodialysis and is associated with adverse outcomes. Although sertraline may improve autonomic dysfunction, which contributes to the pathogenesis of IDH, its efficacy in preventing IDH remains uncertain.

Methods

We conducted a prospective, randomized, double-blind, placebo-controlled, crossover trial in maintenance hemodialysis patients with IDH in ≥25% of sessions. Participants received sertraline or placebo for 4 weeks, followed by a 4-week washout before crossover (total 12 weeks). Sertraline was initiated at 50 mg/day for 1 week and increased to 100 mg/day for weeks 2-4. Primary outcome was the incidence of IDH. Secondary outcomes included IDH incidence stratified by diabetes status, symptomatic IDH, therapeutic interventions, intradialytic blood pressure changes, and adverse events.

Results

Thirty-seven patients were enrolled (mean age 64.0 years; 49% male; median dialysis vintage 24 months). In the intention-to-treat analysis, sertraline significantly reduced IDH episodes compared with placebo (2.5 vs 4.2 episodes per patient, p for treatment effect<0.001, period effect=0.607, sequence effect=0.577). Among diabetic patients, IDH incidence was lower with sertraline (2.5 vs 4.3 episodes per patient, p<0.001), whereas no difference was observed in non-diabetic patients. Sertraline also reduced symptomatic IDH (0.5% vs. 1.4%, p=0.036) and therapeutic interventions (5.2 vs. 8.4 events, p=0.001). Systolic blood pressure and mean arterial pressure at 1- and 3-hours during dialysis were significantly higher with sertraline. Adverse events were comparable.

Conclusions

In maintenance hemodialysis patients with frequent IDH, sertraline significantly reduced IDH episodes, particularly among those with diabetes, decreased symptomatic events and rescue interventions, and improved intradialytic hemodynamic stability.

Autor:innen und Institutionen

ORCID-Profile: Chidchanok Ruengorn, Surapon Nochaiwong, Kajohnsak Noppakun

Zitieren

APA

Kusirisin, P., Ruengorn, C., Nochaiwong, S., & Noppakun, K. (2026). Sertraline Administration to Prevent Intradialytic Hypotension: A Randomized, Double-Blind, Placebo-Controlled Crossover Study (SLATAN Study). American Journal of Nephrology. https://doi.org/10.1159/ajn/ablag035

Vancouver

Kusirisin P, Ruengorn C, Nochaiwong S, Noppakun K. Sertraline Administration to Prevent Intradialytic Hypotension: A Randomized, Double-Blind, Placebo-Controlled Crossover Study (SLATAN Study). American Journal of Nephrology. 2026. doi:10.1159/ajn/ablag035

BibTeX
@article{Kusirisin2026,
  author = {Kusirisin, Prit and Ruengorn, Chidchanok and Nochaiwong, Surapon and Noppakun, Kajohnsak},
  title = {Sertraline Administration to Prevent Intradialytic Hypotension: A Randomized, Double-Blind, Placebo-Controlled Crossover Study (SLATAN Study)},
  journal = {American Journal of Nephrology},
  year = {2026},
  doi = {10.1159/ajn/ablag035}
}
Kostenlos starten →